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Purified human anti-Tn and anti-T 
antibodies specifically recognize 
carcinoma tissues
Natacha Zlocowski1,3, Veronica Grupe2, Yohana C. Garay1, Gustavo A. Nores1, 
Ricardo D. Lardone1 & Fernando J. Irazoqui1
Described in several epithelial cancer cells, Tn- (GalNAcα1-O-Ser/Thr) and T- (Galβ3GalNAcα1-O-Ser/
Thr) antigens are examples of tumor-associated antigens. Increased expression of Tn- and T-antigens 
is associated with tumor invasion and metastasis, and patients with high concentration of anti-Tn and 
anti-T antibodies have a more benign evolution of pathology. Asialofetuin (ASF) and ovine submaxillary 
mucin (OSM) are two glycoproteins that expose T- and Tn-antigen, respectively. In this work, using ASF 
or OSM we affinity-purified anti-T and anti-Tn antibodies from normal human plasma and tested their 
ability to specifically recognize tumor human tissues. Whereas purified anti-T antibodies (purity degree 
increase of 127-fold, and 22% recovery) were mainly IgG, for purified anti-Tn antibodies (purity degree 
enhancement of 125-fold, and 26% yield) the IgM fraction was predominant over the IgG one. IgG2 
subclass was significantly enriched in both purified antibody samples. Purified antibodies did not bind 
normal human tissue (0/42), although recognized malignant tissues from different origin such as colon 
carcinoma (11/77 by anti-Tn; 7/79 by anti-T), breast carcinoma (10/23 by anti-Tn; 7/23 by anti-T), and 
kidney carcinoma (45/51 by anti-Tn; 42/51 by anti-T). Our results suggest that purified human anti-Tn 
and anti-T antibodies have a potential as anti-tumor therapeutic agents; restoring their levels in human 
sera could positively affect the evolution of patients with epithelial tumor pathologies.
The phenotype of epithelial cancer cell is greatly conditioned by glycoconjugates from glycoproteins, glycolip-
ids and glycosaminoglycans. These terminal glycans are relevant in the cell-cell and cell-extracellular matrix 
communication, and critical points in the cancer cell invasion, proliferation and dissemination processes1. 
O-GalNAc glycans are a type of protein post-translational modification significantly affected in epithelial can-
cer cells2. In polymeric biosynthesis of O-GalNAc glycans, the first step occurring is the covalent linkage of 
N-acetylgalactosamine (GalNAc) to selected Ser/Thr residues of the acceptor protein to yield GalNAcα1-O-Ser/
Thr (Tn-antigen), a reaction catalyzed by polypeptide-N-acetylgalactosaminyltransferases (ppGalNAc-Ts)3. 
The second monosaccharide linked to GalNAcα1-O-Ser/Thr may be galactose (Gal) or N-acetylglucosamine 
(GlcNAc), to generate core 1 glycan (Galβ3GalNAcα1-O-Ser/Thr, also called T-antigen), or core 3 glycan 
(GlcNAcβ3GalNAcα1-O-Ser/Thr), respectively. T-antigen biosynthesis involves Core 1 β3Gal-T (C1GalT), an 
ubiquitous enzyme found in most mammalian cells. Core 3 glycans are predominant in colonic and salivary 
mucins, where Core 3 β3GlcNAc-T catalyzes their biosynthesis. The β6-GlcNAc-T action on T-antigen and core 
3 glycans yield core 2 and core 4 glycans, respectively. Galβ3/4GlcNAc units give rise to the backbone region of 
O-GalNAc glycans. Fucose and N-acetylneuraminic acid are frequent capping residues in these regions4.
O-GalNAc glycans present on carcinoma cells are commonly truncated structures exposing cryptic regions 
that are normally hidden. Tumor associated-antigens (TAAs) are terminal residues chemically well know with 
more often in cancer cells than normal cells. Tn- and T-antigens are examples of TAAs described in several 
epithelial cancer cells5. The increased expression of T- and Tn-antigens is associated with tumor invasion and 
metastases6.
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Normal human sera contain multiple antibodies recognizing specific glycan residues7, and different hypothe-
sis attempt to explain the origin of natural anti-glycan antibodies8. Natural anti-Tn and anti-T antibodies are pres-
ent in normal human sera9, and studies of anti-Tn and anti-T antibodies in patients with epithelial carcinomas 
showed reduced levels of these anti-glycan antibodies10. In addition, pathology evolution of patients with high 
concentration of anti-Tn and anti-T antibodies is more benign11. These results suggest that restitution of human 
anti-Tn and anti-T antibodies should positively affect the evolution of patients with epithelial tumor pathologies.
Immunotherapy modulates the host’s immune response to TAAs, eradicates cancer cells by reducing host 
tolerance to TAAs and provides protection against the disease12–14. Passive immunotherapies, like monoclonal 
antibodies or engineered T-cell based therapies, are targeted to tumor cells by recognizing TAAs. Several immu-
notherapy strategies have been tested for anti-tumor responses using monoclonal antibodies against receptor 
tyrosine kinases like members of the EGFR family (cetuximab, pertuzumab, and trastuzumab)15,16 or against their 
ligands like VEGF (bevacizumab)17, involved in tumor cell proliferation or angiogenesis, respectively.
In the present study we purified two populations of antibodies (anti-Tn and anti-T) from pooled human 
plasma and evaluated their ability to recognize human carcinoma tissue, aiming to uncover potential applications 
in antineoplastic therapy.
Results
Purification of anti-glycan antibodies. Asialofetuin (ASF) and ovine submaxillary mucin (OSM) are 
two highly glycosylated antigens. ASF mainly exposes terminal T-antigen glycans, whereas OSM shows multiple 
terminal Tn- and sialyl Tn-antigens18,19. By immobilizing ASF and OSM in Sepharose, these terminal glycans were 
used as ligands for affinity chromatography purification of human antibodies. Gammaglobulin fraction from 
pooled human plasma was offered to immobilized antigens. After washing the columns, retained proteins were 
eluted and analyzed. The purity of eluted proteins was evaluated by SDS-PAGE stained with Coomassie Brilliant 
Blue (CBB), and immunoglobulin isotypes were identified by western blot (WB) using anti-human IgG, IgM and 
total immunoglobulin antibodies (Fig. 1).
SDS-PAGE stained with CBB showed highly purified proteins, with molecular weight corresponding to 
human immunoglobulins. WB showed that purified anti-ASF antibodies are mainly IgG with reduced proportion 
of IgM, whereas in the purified human anti-OSM antibodies the IgM fraction is important with respect to IgG. To 
know the purification degree and yield of each purified antibody, proteins were measured by bicinchoninic acid 
assay, and human immunoglobulins were measured by ELISA using HRP-labeled IgG anti-human total immuno-
globulin antibodies (Fig. 2). Affinity chromatography for human antibodies recognizing ASF increased the purity 
degree 127-fold with 22% recovery (Table 1), whereas the purification of anti-OSM antibodies enhanced 125-fold 
the specific activity with 26% yield (Table 2). Further characterization of both purified antibodies showed a very 
important enrichment of IgG2 subclass (Tables 1 and 2).
Carbohydrate specificity of purified anti-glycan antibodies. The recognition of purified anti-ASF 
and anti-OSM antibodies to the corresponding antigen used during the affinity chromatography purifi-
cation are shown in Fig. 3. Carbohydrate specificity of purified antibodies was evaluated by competitive 
Figure 1. Analysis of purified proteins obtained by affinity chromatography using immobilized ASF (A) 
or OSM (B) antigen. Quadruplicates for each eluted sample were seeded in polyacrylamide gels to analyze 
degree of protein purity by staining with Coomassie Brilliant Blue (a), or by western blot detecting heavy chain 
presence of human IgG (b), human IgM (c), or human total immunoglobulins (d) by using HRP-labeled IgG 
anti-human IgG, or IgM or total immunoglobulins antibodies, respectively. Color reaction was developed as 
described in Methods.
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ELISA using sugars related to Tn- and T-antigen. Interaction of anti-ASF antibodies was significantly inhib-
ited with Galβ3GalNAcαBzl, whereas glucose did not induce inhibition (Table 3). Binding inhibition with 
Galβ3GalNAcαBzl revealed the presence of anti-T antibodies in this purified antibody sample. OSM-affinity 
Figure 2. Measurement of total human immunoglobulin by ELISA. Standard curve was developed using 
different concentrations of purified human total immunoglobulins (Gammaglobulina-T, Laboratorio de 
Hemoderivados) adsorbed to wells of microtiter plates and detected with HRP-labeled IgG anti-total human 
immunoglobulin antibodies. Color reaction was developed as described in Methods. Concentration of 
total human immunoglobulin from different samples was measured extrapolating each optical density to 














1 2 3 4
Initial Igs 500,000 271 5.4 × 10−4 1 100 10 65 25 7 3
Eluted Igs 871 60 0.069 127 22 14 nd 100 nd nd













1 2 3 4
Initial Igs 500,000 425 8.5 × 10−4 1 100 10 65 25 7 3
Eluted Igs 1,025 109 0.106 125 26 0.8 nd 83 17 nd
Table 2. Purification of anti-OSM antibodies containing anti-Tn antibodies from normal human plasma. nd: 
not detected.
Figure 3. Recognition of purified antibodies to antigens by ELISA. Several concentrations of antibodies 
purified by affinity chromatography were faced to the corresponding ASF (A) or OSM (B) antigen adsorbed 
to wells of microtiter plates. After incubated for 2 h at RT, the interacting antibodies were detected with HRP-
labeled IgG anti-total human immunoglobulin antibodies. Color reaction was developed as described in 
Methods.
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chromatography yielded anti-Tn antibodies, as showed by the important inhibition with GalNAcαBzl whereas 
control (glucose) did not show inhibition (Table 4).
Anti-Tn and anti-T antibodies specifically recognize human carcinoma tissues. The capacity 
of human purified anti-Tn and anti-T antibodies to recognize human carcinoma tissues was analyzed by tis-
sue micro-arrays (TMAs). Human TMAs from normal breast, kidney, colon, skin, placenta, cervix, fallopian 
tube, pancreas, amygdale, endometrium, small intestine, ovary, spleen, and brain tissues, as well as carcinomas 
from skin, colon, breast, and kidney tissues were assayed to study carcinoma recognition of purified antibodies. 
Representative images of human normal and malignant tissues, and human cell lines with negative and positive 
staining are shown in Fig. 4. Purified anti-Tn and anti-T antibodies did not recognize (0/42) normal human 
tissues (Fig. 5). Human melanoma tissues were not recognized (0/12) by purified anti-Tn or anti-T antibodies. 
Human carcinoma colon tissues were positively stained in 14% (11/77) by anti-Tn antibodies and in 8.9% (7/79) 
by anti-T antibodies. In addition, breast carcinoma tissue showed positive immunoreactivity in 43% (10/23) and 
30% (7/23) by anti-Tn and anti-T antibodies, respectively. Table 5 shows features of human breast carcinomas. 
Also, human breast tumor T47D cell line showed strong positive recognition by purified antibodies (Fig. 4). 
Human embryonic kidney (HEK-293) cells were less immunoreactive that tumor T47D cells with purified 
anti-Tn and anti-T antibodies (Fig. 4). Human kidney carcinoma was the most recognized tissue by these anti-
bodies, showing positive staining in 88% (45/51) by anti-Tn antibodies and in 82% (42/51) of carcinoma tissues 
by anti-T antibodies (Fig. 5). Table 6 shows characteristic of human kidney tumor tissues and the recognition of 
purified antibodies.
Positive recognition of purified anti-Tn and anti-T antibodies was analyzed in relation to carcinoma malig-
nancy state (Fuhrman degree classification). Anti-Tn antibodies identified 45% (5/11) degree 2 human breast 
carcinomas, and 36% (4/11) degree 3 (Fig. 6A). Degree 2 human breast carcinoma tissues showed 27% (3/11) 
positive recognition by anti-T antibodies, and identical result was the recognition (3/11) of degree 3 breast carci-
noma tissues. Kidney carcinoma TMAs revealed that anti-Tn antibodies identified 89% (32/36) degree 2 and 83% 
(10/12) degree 3 carcinoma tissues, whereas anti-T antibodies recognized 80% (29/36) degree 2 and 83% (10/12) 
degree 3 carcinoma tissues (Fig. 6B).
Discussion
Passive immunotherapy of patients with cancer pathologies implicate incorporation of molecules addressed 
against the tumor. Thus, specific molecules are used to decrease the transformation, proliferation and survival 
of cancer cells. Mouse monoclonal humanized antibodies (mAbs) such as obinutuzumab, rituximab and trastu-
zumab are examples of successful passive immunotherapies in the treatment of cancer patients20. However, these 
mAb treatments showed side effects such as ocular and neuro-ophthalmic toxicity, skin toxicities with different 
severities (from mild lichenoid reaction to severe toxic epidermal necrolysis), increased risk factors in develop-
ment of hypogammaglobulinemia and infections (post-rituximab), and increased cumulative incidence of breast 
cancer brain metastases after HER2-directed therapy (trastuzumab)21–24. In the present work, we obtained human 
anti-Tn and anti-T antibodies that specifically recognize human carcinoma tissues, with potential use for restora-
tion of anti-glycan antibody concentrations of patients presenting epithelial tumor pathologies.
Immobilized ASF and OSM allowed the purification of natural antibodies present in normal human plasma. 
Both purified antibodies enhanced more than 120-times the purification degree compared to plasma pres-
ence. Related to immunoglobulin isotype of purified antibodies, anti-ASF antibodies were mainly IgG whereas 
anti-OSM antibodies contained IgM in similar proportion to IgG. In agreement with this purification, the pres-
ence of IgM and IgG2 subclass as constitutive of natural anti-glycan antibodies has been frequently described25,26.
Carbohydrate Inhibitor (%) 6 (mM) 3 (mM) 1,5 (mM) 0,75 (mM)
Galβ3GalNAcαBzl 39 24 15 5
Glc 6 5 3 4
Table 3. Carbohydrate recognition of anti-T antibodies by competitive assay1. 1Competitive assay using 
carbohydrates as inhibitors of anti-ASF antibody recognition. Different concentration of carbohydrates 
preincubated with anti-ASF antibodies showed the significance of sugar residue in the antigen recognition. 
Galβ3GalNAcαBzl, structure related to T-antigen, is important inhibitor of antibody interaction whereas 
glucose (Glc) has not effect (control).
Carbohydrate Inhibitor (%) 6 (mM) 3 (mM) 1,5 (mM) 0,75 (mM)
GalNAcαBzl 32 33 31 5
Glc 4 2 1 2
Table 4. Carbohydrate recognition of anti-Tn antibodies by competitive assay1. 1Competitive assay using 
carbohydrates as inhibitors of anti-OSM antibody recognition. Different concentrations of carbohydrates 
preincubated with anti-OSM antibodies showed the significance of sugar residue in the antigen recognition. 
GalNAcαBzl, structure related to Tn-antigen, is important inhibitor of antibody interaction whereas glucose 
(Glc) has not effect (control).
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The classical way to study glycan recognition of proteins is through competitive assays with soluble carbohy-
drates. This useful tool allowed us to observe that, upon purification, human natural anti-ASF antibodies recog-
nize related Thomsen-Friedenreich structure (T antigen), and that human natural anti-OSM antibodies recognize 
Tn antigen. Thus, both purified antibodies showed the expected glycan recognition specificity.
The ability of these purified anti-glycan antibodies to recognize human carcinomas was studied using TMAs. 
Purified anti-T and anti-Tn antibodies did not interact with normal human tissues, a consistent observation 
since these antibodies were purified from normal individuals. This represents an advantage compared to observa-
tions from previous antibody approaches: therapeutic use for several mouse humanized monoclonal antibodies 
reported side effects as skin and neuro-ophthalmic toxicities, thus suggesting recognition of normal tissues23,24.
Purified anti-Tn and anti-T antibodies did not show capacity to recognize human melanomas, and colon car-
cinomas were poorly recognized. The binding ability of these antibodies improved for breast human carcinomas 
tissues (43% for anti-Tn antibodies and 30% for anti-T antibodies), and they were even more efficient in recogniz-
ing human kidney carcinoma tissues. Trastuzumab (anti-Her2 antibody) is present in the pharmaceutical market 
Figure 4. Representative examples of human normal and carcinoma tissues, and human cell lines in the 
analysis of anti-Tn and -T antibody recognition. No recognition (−) and positive recognition (+, brown 
color) of different human tissues/cells was observed by using human purified anti-Tn and -T antibodies. 
After incubated the TMAs/cells with primary anti-Tn or -T antibodies for 2 h at RT, interacting antibodies 
were detected with HRP-labeled IgG anti-total human immunoglobulin antibodies. Color reaction was 
developed with H2O2 and diaminobenzidine (brown color), using hematoxylin for contrast (blue color) in 
TMAs, as described in Methods. Human normal spleen (A), pancreas (B), skin (C), small intestine (D), 
placenta (E), colon (F), breast (G), kidney (H), brain (I), cervix (J), fallopian (K) and hypophysis (L) showed 
negative recognition by anti-Tn antibodies. Representative examples of human breast carcinoma tissues with 
positive recognition (M) and no recognition (N) by anti-T antibodies as well as positive recognition (O) 
and no recognition (P) to human kidney carcinoma tissues. Human breast cancer T47D cells show positive 
staining with anti-Tn antibodies (Q) and negative staining without the primary anti-Tn antibodies (R). Lower 
recognition of anti-Tn antibodies to human embryonic kidney HEK-293 cells (S), and negative staining was 
observed without the primary anti-Tn antibodies (T).
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having only 3% Her2-positive immunostaining across human carcinomas, with frequencies ranging from 0.4% 
in hepatocellular carcinoma to 12.4% in bladder cancer27. The antibodies obtained herein have better recognition 
ability to human carcinomas than trastuzumab, thus deserving further attention.
The analysis of carcinoma Fuhrman grades related to positive recognition for the obtained antibodies showed 
no differences. Anti-Tn and anti-T antibodies recognized equally well carcinomas with Fuhrman degree 2 and 
3 from human breast and kidney tissues. This fact shows that these antibodies could be useful for patients’ treat-
ment with early Fuhrman grades of breast and kidney carcinomas, such as degree 2.
In summary, we have outlined the production of two natural antibodies from normal human plasma. Their 
relevant capacity to efficiently and specifically recognize human carcinoma tissues brings hope about their poten-
tial use as antitumoral antibodies to restitute the anti-Tn and anti-T antibody concentrations in patients with 
carcinoma pathologies.
Figure 5. Recognition of purified antibodies to human tissues by TMAs. Summary of TMAs results for anti-Tn 
and anti-T antibodies. Percentage of non-recognized samples is shown as clear areas, whereas percentage of 
recognized samples is depicted as dark gray areas. Number of total samples for each tissue is noted inside each 
pie chart.
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Methods
Human plasma. Normal human plasma samples from healthy donors were collected by Laboratorio de 
Hemoderivados, Universidad Nacional de Córdoba (UNC), Argentina. Written informed consent was obtained 
from every donor. All plasma demonstrated negative serology tests for common infectious diseases. A plasma 
pool from 100 healthy donors was used as starting material for antibody purification. All procedures were 
approved by the Ethics Committee of CIQUIBIC-CONICET (UNC). All experiments were performed in accord-
ance with Ethical Guidelines on Research Involving Human Subjects28.
Antibody purification. Human antibodies were purified by affinity chromatography using asialofe-
tuin (ASF; Sigma-Aldrich, St. Louis, MO, USA) or ovine submaxyllary mucin (OSM; Accurate Chemical & 
Scientific Corporation, Westbury, NY, USA) immobilized in cyanogen-bromide-activated Sepharose 4B column 
(Sigma-Aldrich, St. Louis, MO, USA). Gammaglobulin fraction from pooled human plasma were loaded into 
ASF- or OSM-Sepharose column, washed with 0.1 M Tris-HCl (pH 8.0) and 0.01 M Tris-HCl (pH 8.0), and eluted 
with 0.2 M glycine-HCl (pH 2.5). Specific antibodies were recovered in 1 M Tris (pH 8.0). Affinity-purified anti-
bodies were dialyzed against PBS and stored at −18 °C until use.
SDS-PAGE and western blotting. Homogeneity of purified antibodies was confirmed by SDS-PAGE and 
Coomassie Brilliant Blue staining29. To evaluate their isotypes, purified antibodies were subjected to SDS-PAGE, 
and electrotransferred membranes were blocked with 1% skim milk in PBS for 60 min at room temperature (RT). 
HRP-labeled IgG anti-human IgG, anti-human IgM, or anti-total immunoglobulin antibodies (Sigma-Aldrich, St. 
Louis, USA; 1/1000 dilution in 0.05% Tween 20 in PBS) were incubated for 2 h at RT and washed with PBS. Color 
reaction was developed using 0.1 mg/ml 4-chloro-1-naphthol and 0.02% H2O2 in methanol-TBS for 20 min, and 
stopped by washing with distilled water.
Measurement of total proteins and immunoglobulins. A bicinchoninic acid assay was used to 
measure total proteins with BSA as the standard (Pierce, Thermo Scientific). To measure total immunoglobulin 
concentration, wells of microtiter plates were coated with several concentrations of purified total human immu-
noglobulins (Gammaglobulina-T, Laboratorio de Hemoderivados, UNC, Argentina) in 0.1 M carbonate buffer 
(pH 9.5) overnight at 4 °C. After blocking with PBS containing 1% BSA and 0.05% Tween 20, plates were incu-
bated with 1:1000 HRP-conjugated IgG anti-human total immunoglobulin antibodies (Sigma-Aldrich, St. Louis, 
USA) in PBS-T, for 2 h at RT. Plates were washed 4x with PBS-T, and color reaction was developed using 2 mg/ml 
o-phenylenediamine and 0.02% H2O2 in 0.1 M sodium citrate (pH 5.0), at RT for 10 min. Reaction was stopped 
by addition of 0.5 M sulfuric acid. Absorbance values were read at 490 nm with a microplate reader. Similarly, 












Invasive ductal carcinoma Quadrantectomy 2.0 1/10 2 0, negative 0, negative
Lobular carcinoma Mastectomy 4.0 8/12 4 1, negative 1, negative
Invasive ductal carcinoma Quadrantectomy 2.5 0/10 3 3, positive 3, positive
Invasive ductal carcinoma Quadrantectomy 2.5 0/1 3 0, negative 0, negative
Invasive ductal carcinoma Mastectomy 3.8 0/14 2 2, positive 3, positive
Invasive ductal carcinoma nd 5.0 1/1 2 3, positive 2, positive
Invasive ductal carcinoma Mastectomy 9.0 nd 3 1, negative 0, negative
Invasive ductal carcinoma Mastectomy 1.8 nd 3 1, negative 3, positive
Invasive ductal carcinoma Mastectomy 3.6 1/11 2 2, positive 3, positive
Lobular carcinoma Mastectomy 4.0 0/8 2 1,negative 2, positive
Invasive ductal carcinoma Mastectomy nd 6/6 2 0, negative 2, positive
Invasive ductal carcinoma Mastectomy 4.0 nd 3 0, negative 0, negative
Invasive ductal carcinoma Quadrantectomy 2.0 nd 2 0, negative 0, negative
Invasive ductal carcinoma Mastectomy 6.0 6/6 3 0, negative 1, negative
Invasive ductal carcinoma Quadrantectomy 4.0 nd 3 3, positive 3, positive
Invasive ductal carcinoma nd 4.0 nd 3 1, negative 2, positive
Lobular carcinoma Quadrantectomy 2.5 0/6 2 0, negative 0, negative
Invasive ductal carcinoma Mastectomy 2.6 0/12 2 0, negative 0, negative
Invasive ductal carcinoma Mastectomy 2.0 0/14 2 0, negative 1, negative
Invasive ductal carcinoma Quadrantectomy 2.0 nd 3 0, negative 0, negative
Invasive ductal carcinoma Quadrantectomy 1.5 0/14 3 2, positive 1, negative
Invasive ductal carcinoma Quadrantectomy nd nd 3 0, negative 0, negative
Invasive ductal carcinoma Mastectomy 2.5 0/3 1 2, positive 2, positive
Table 5. Characteristics of analyzed human breast tissues and recognition of purified antibodies. nd: not 
determined.
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concentrations determined from standard curves of human IgG and IgM, respectively. Radial immunodiffusion 
for measuring human IgG1, IgG2, IgG3 and IgG4 was performed as suggested by manufacturer (The Binding Site 
Inc., San Diego, USA) and the concentrations were determined from standard curves.
Histology Fuhrman grade Anti-T recognition (score, assessment) Anti-Tn recognition (score, assessment)
Clear cell renal carcinoma 3 0, negative 0, negative
Clear cell renal carcinoma 2 0, negative 0, negative
Clear cell renal carcinoma 2 1, negative 2, positive
Clear cell renal carcinoma 3 2, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 2, positive 3, positive
Clear cell renal carcinoma 2 0, negative 3, positive
Clear cell renal carcinoma 2 2, positive 3, positive
Clear cell renal carcinoma 4 3, positive 3, positive
Clear cell renal carcinoma 2 2, positive 2, positive
Clear cell renal carcinoma 1 3, positive 3, positive
Clear cell renal carcinoma 3 2, positive 3, positive
Clear cell renal carcinoma 2 0, negative 0, negative
Type 1 papillary renal cell carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 3 1, negative 1, negative
Clear cell renal carcinoma 3 3, positive 3, positive
Clear cell renal carcinoma 2 2, positive 3, positive
Type 2 papillary renal cell carcinoma 2 2, positive 3, positive
Oncocytic renal tumor cells 2 2, positive 2, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 2, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 0, negative 2, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 3 3, positive 3, positive
Clear cell renal carcinoma 2 0, negative 0, negative
Clear cell renal carcinoma 2 3, positive 3, positive
Type 1 papillary renal cell carcinoma 1 3, positive 3, positive
Clear cell renal carcinoma 3 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 3 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 2, positive 2, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 3 3, positive 3, positive
Clear cell renal carcinoma 2 2, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 0, negative 0, negative
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Clear cell renal carcinoma 2 3, positive 2, positive
Clear cell renal carcinoma 3 3, positive 3, positive
Clear cell renal carcinoma 3 3, positive 3, positive
Type 2 papillary renal cell carcinoma 2 2, positive 2, positive
Clear cell renal carcinoma 3 3, positive 2, positive
Clear cell renal carcinoma 2 3, positive 3, positive
Table 6. Characteristics of analyzed human kidney tissues and recognition of purified antibodies.
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Antigen recognition of antibodies. Antigen recognition of antibodies was measured by ELISA. Wells of 
microtiter plates were coated with antigen (ASF or OSM) in 0.1 M carbonate buffer (pH 9.5) overnight at 4 °C. 
After blocking with PBS containing 1% BSA and 0.05% Tween 20, we incubated plates with various dilutions of 
purified antibodies in PBS-T, for 2 h at RT. Plates were washed 4x with PBS-T, then incubated with 1:1000 diluted 
HRP-conjugated IgG anti-human total immunoglobulin antibodies for 1 h at RT. Plates were washed 4x with 
PBS-T, and color reaction was developed as previously described.
Antibody specificity by competitive ELISA. Steps of competitive ELISA were developed similarly to 
previous item, except that the optimal antibody dilution was preincubated with each carbohydrate for 1 h before 
addition to wells. The optimal antibody dilution showing ∼1.0 optical density against the target antigens was 
assayed. Results were expressed as the percent inhibition caused by the competition of soluble sugar presence.
Cell lines. Human breast adenocarcinoma (T47D), and human embryonic kidney (HEK-293) cells were from 
CIQUIBIC-CONICET/Dept. of Biological Chemistry, Universidad Nacional de Córdoba, Argentina. Human 
cell lines were grown at 37 °C in an incubator (10% CO2 atmosphere) in Dulbecco’s modified Eagle’s medium 
(DMEM) (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal calf serum (FCS), 1 mM sodium pyruvate, 
and nonessential amino acids.
Tissue microarrays (TMAs). All procedures, performed in accordance with Ethical Guidelines on Research 
Involving Human Subjects28 and with ethical standards as laid down in the 1964 Declaration of Helsinki and 
its later amendments, were approved by the Ethics Committee of CIQUIBIC-CONICET; informed consent 
was obtained from the patients. Paraffin-embedded tissues were selected from histological file and used in a 
blind-retrospective manner. Representative areas from normal tissues (n = 42), skin melanoma (n = 12) and car-
cinomas (colon n = 77, breast n = 23, kidney n = 51) were carefully marked on H&E-stained sections. Tissue 
cores of 2 mm diameter were obtained from each specimen and were precisely arrayed into a new paraffin block. 
4 μm thickness sections of this new block were cut and mounted on polarized slides to future staining.
Figure 6. Positive recognition of purified anti-Tn and anti-T antibodies in relation to carcinoma malignancy 
state (Fuhrman grade). Summary of TMAs results for anti-Tn and anti-T antibodies for breast (A) and 
kidney (B) human carcinoma tissues. Percentage of non-recognized samples is shown as clear areas, whereas 
percentage of recognized samples is depicted as dark gray areas. Number of total samples for each tissue is noted 
inside each pie chart. Fuhrman grade (1–4) is indicated to the left.
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Immunohistochemistry. Paraffin sections were dewaxed in a xylene-ethanol series. Endogenous per-
oxides were removed by methanol 3.5% hydrogen peroxide incubation at room temperature for 30 minutes. 
Heat-induced epitope retrieval was performed with a 0.1 M sodium citrate buffer (pH 6.0). A 1-hour blocking 
step with 10% goat serum was done prior to adding primary antibody followed by HRP-conjugated anti-human 
total immunoglobulin antibodies (Sigma-Aldrich). Detection was performed using 3,3′-diaminobenzidine and 
counterstained with Biopur hematoxylin. Sections were then dehydrated through a series of ethanol to xylene 
washes and cover slipped with Canada Balsam. Images of representative tissue spots were taken at 40× magnifi-
cation with a Leica microscope.
Criteria for classification of staining patterns. Scores were defined in terms of staining pattern. Score 
0: No observable staining, or membrane staining that is incomplete and is faint/barely perceptible in ≤10% of 
invasive tumor cells. Score 1: Incomplete membrane staining that is faint/barely perceptible in ≤10% of invasive 
tumor cells. Score 2: Circumferential membrane staining that is incomplete and/or weak/moderated in >10% of 
invasive tumor cells, or complete and circumferential intense membrane staining in ≤10% of invasive tumor cells. 
Score 3: Homogeneous, dark, circumferential (chicken wire) pattern in >10% of invasive tumor cells.
Scores 0 and 1 were assessed as negative, whereas scores 2 and 3 were assessed as positive.
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